Scotiabank lifted its Merck target to $136 and kept an ‘Outperform’ rating, implying a 17% upside.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
How Merck Is Preparing For The Patent Cliff Of Its Blockbuster Cancer Drug Keytruda
Scotiabank lifted its Merck target to $136 and kept an ‘Outperform’ rating, implying a 17% upside.